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DObjective: Aortic cusp extension valvuloplasty is increasingly used in the management of children and adoles-
cents with aortic stenosis or regurgitation. The durability of this approach and the freedom from valve replacement
are not well defined. A study was undertaken to investigate outcomes.
Methods: From July 1987 to November 2008, 142 patients aged less than 19 years underwent aortic cusp exten-
sion valvuloplasty in the form of pericardial cusp extension and tricuspidization (when needed). Three patients
with truncus arteriosus and severe truncal valve insufficiency were excluded. From the available follow-up
data of 139 patients, 50 had bicuspid aortic valves, 40 had congenital aortic valve stenosis, 41 had combined con-
genital aortic valve stenosis/insufficiency, and 8 had other diagnoses. Median follow-up was 14.4 years (0.1–
21.4). Long-term mortality and freedom from aortic valve replacement were studied.
Results: There were no early, intermediate, or late deaths. Z-values of left ventricular end-diastolic dimension,
aortic annulus, aortic sinus diameter, and sinotubular junction diameter before aortic valve replacement were
4.2  3.11, 2.3  1.25, 4.4  1.23, and 1.84  1.28, respectively. During the follow-up period, 64 patients
underwent aortic valve reinterventions. The Ross procedure was performed in 32 of 139 patients (23%) under-
going aortic cusp extension valvuloplasty. Other aortic valve replacements were undertaken after 16 aortic cusp
extension valvuloplasties (11.5%). Freedom from a second aortic cusp extension valvuloplasty or aortic valve
replacement at 18 years was 82.1%  4.2% and 60.0%  7.2%, respectively.
Conclusion: Aortic cusp extension valvuloplasty is a safe and effective surgical option with excellent survival
and good long-term outcomes in children and adolescents. The procedure provides acceptable durability and
satisfactory freedom from aortic valve replacement. (J Thorac Cardiovasc Surg 2010;139:933-41)Since the initial report of aortic valve repair,1 there have
been various techniques described. Available surgical
options for the treatment of aortic insufficiency (AI) or aortic
stenosis (AS) in young patients include various techniques
of aortic valve repair, surgical aortic valvuloplasty, and
aortic valve replacement (AVR) with mechanical, biopros-
thetic, or autologous pulmonary valves.2-5 Results have
been improving with better anatomic understanding and
operative and postoperative management. Aortic cusp exten-
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The Journal of Thoracic and Caneeded) may have important advantages in children relative
to the alternatives, particularly with regard to freedom from
reoperation related to a small mechanical prosthesis, avoid-
ance of anticoagulation, and potential mid and late disadvan-
tages of the Ross procedure related to the pulmonary
autograft and implanted homograft. Few reports of ACEV
in children, most with limited follow-up, have been pub-
lished.6-12 Clinical analysis on patients who underwent
ACEV was conducted. Assessment of valvar morphologic
characteristics was performed. The impact of ACEV on sur-
vival and freedom from reoperation was assessed, and fac-
tors associated with improved outcome were explored.
MATERIALS AND METHODS
The Heart Institute for Children database was analyzed, and all patients
undergoing ACEV with or without tricuspidization from July 1987 to No-
vember 2008 were included. A retrospective chart review analysis was
conducted with regard to preoperative and postoperative data. Current
follow-up data were available for all patients.
Preoperative echocardiography was used. AI was graded as (1) none or
trace; (2) mild (no left ventricular [LV] dilation, no retrograde flow in the
descending aorta, AI vena contracta width< 4 mm); (3) moderate (LV
end-diastolic volume or LV end-diastolic dimension [LVEDD] z-value>
2 and< 4, retrograde flow in the descending aorta, vena contracta 4–6
mm); or (4) severe (LV end-diastolic volume or LVEDD z-value>4, retro-
grade flow in the descending aorta, vena contracta>6 mm). AS was esti-
mated by Doppler evaluation, and the peak instantaneous gradient (PIG)
was recorded. AS was categorized as mild (PIG< 40 mm Hg), moderaterdiovascular Surgery c Volume 139, Number 4 933
TABLE 1. Demographics and patient characteristics
Aortic cusp extension valvuloplasty
Patient characteristics
Age at surgery (y) 9.3  2.7
Age at surgery (y): 0–2 25 (18%)
Age at surgery (y): 3–6 36 (25.9%)
Age at surgery (y): 7–11 20 (14.4%)
Age at surgery (y): 12–19 58 (41.7%)
Weight at surgery (kg) 32.71  9.74
Gender 86 male/53 female
Turner’s syndrome 1
Primary aortic valve diagnosis
BAV 50
Combined congenital AS/AI 41
Congenital AS 40
d-TGA/post-ASO AI 2
Rheumatic carditis (AI) 2
Aortic valve endocarditis/aortic root abscess 3 (2/1)
Iatrogenic post-VSD closure AS 1
Associated cardiac anomalies
Coarctation of aorta 10
Ventricular septal defect 5
Subaortic stenosis 2
Congenital mitral valve stenosis 2
Abbreviations and Acronyms
ACEV ¼ aortic cusp extension valvuloplasty
AI ¼ aortic insufficiency
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
BAV ¼ bicuspid aortic valve
CPB ¼ cardiopulmonary bypass
LV ¼ left ventricular
LVEDD ¼ left ventricular end-diastolic dimension
PIG ¼ peak instantaneous gradient
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D(PIG 41–75 mm Hg), or severe (PIG>76 mm Hg). Aortic valve annulus
and root diameters were measured from parasternal long-axis images,
with the root diameter taken as the maximum dimension at the level of
the sinuses.
LV dimensions, volumes, and mass were measured and calculated from
apical 4-chamber and cross-sectional echocardiographic images. Short-axis
LVEDD and LV end-systolic dimension were measured. All data were
indexed to body surface area and reported as z-value.
This study was approved by the institutional review board of Advocate
Hope Children’s Hospital. The institutional review board waived the need
for patient consent.
Interrupted aortic arch 1
Coronary fistula 1
Atrioventricular septal defect 1
Idiopathic dilated cardiomyopathy 1
Taussig–Bing anomaly 1
Additional surgical procedures
Before first ACEV
Initial valvuloplasty-valvotomy
(our facility/outside facility)
67 (24/43)
Aortic coarctation repair 10
ASO 3
IAA repair with VSD closure 1
With the first ACEV
Mitral valvuloplasty for MS or MR 3
Ascending aorta reconstruction for
supravalvar AS
2
Subaortic membrane resection 2
Coronary fistula ligation 1
AI, Aortic insufficiency; AS, aortic stenosis; ACEV, aortic cusp extension valvulo-
plasty; BAV, bicuspid aortic valve; d-TGA, d-transposition of the great arteries;
VSD, ventricular septal defect; ASO, arterial switch operation; MS, mitral stenosis;
MR, mitral regurgitation; IAA, interrupted aortic arch.Clinical Management Protocol and Surgical
Technique
Patient Characteristics. From July 1987 to November 2008,
142 patients aged less than 19 years underwent ACEV in the form of peri-
cardial cusp extension and tricuspidization (when needed). Three patients
with truncus arteriosus and severe truncal valve insufficiency, who require
valvuloplasty, were excluded. Patients with isolated commissuroplasty/
commissurotomy, isolated cusp tear repair, or annular reduction without al-
teration of the valve leaflets were excluded. Patients with univentricular
pathway, morphologically right ventricle functioning as systemic ventricle,
and other associated causes of LV volume overload were excluded. During
the same period, 29 patients had AVR without prior ACEV. From the avail-
able follow-up data of 139 patients, 50 had an initial diagnosis of bicuspid
aortic valves (BAVs), 40 had congenital AS, 41 had combined congenital
AS and aortic insufficiency (AI), and 8 had other diagnoses (Table 1). AI
causes were classified as (1) congenital, (2) BAVs, (3) due to trauma during
other cardiac interventions, (4) due to transcatheter or surgical treatment of
congenital valvular AS, (5) endocarditis related, (6) rheumatic carditis re-
lated, or (7) secondary to an abnormal neoaortic (native pulmonary) valve
or root after arterial switch operation. Twenty-six patients (18.7%) had as-
sociated cardiovascular anomalies, and 1 patient had Turner’s syndrome
(Table 1). Patients were not initially randomized; rather, each case was man-
aged according to each of 4 surgeons’ preference and not on strict anatomic
or functional criteria. Later in the series (since 1998), patients selected for
ACEV had a normally sized aortic annulus (z-value1.5) without LV hy-
poplasia or mitral valve hypoplastic annulus (z-value 2.0). Assessment
of severity of valve dysfunction and timing for ACEV involved several
echocardiographic/Doppler-derived indices. Indications for ACEV were
moderate or severe AI, moderate AS, or a combination of moderate-to-se-
vere AS and moderate AI. Specifically, patients with isolated AS of 40
mm Hg or greater with a normally sized valve annulus (as described above)
associated with progressive LV hypertrophy were considered for ACEV. In
isolated AI, a ratio of regurgitant jet/annulus diameter of 35% or greater and
progressive increase in LVEDD z-value ofþ2.5 or greater in 2 consecutive
measurements constituted objective indications for intervention. The mean934 The Journal of Thoracic and Cardiovascular Surgage at the time of ACEV was 9.3  2.7 years. Seventy-five patients were
aged less than 10 years. The mean weight of patients undergoing ACEV
was 32.71 9.74 kg. Themedian follow-upwas 14.4 years (0.1–21.4 years)
(Table 1).
Operative Technique
Via a median sternotomy, a piece of autologous pericardium is har-
vested, thoroughly cleaned of all fatty tissue and adhesions, treated with
0.625% glutaraldehyde solution for 3 minutes, and kept moist with normal
saline.ery c April 2010
FIGURE 1. ACEV with tricuspidization. Each valve cusp is evaluated as to the extent of tissue deficiency, the shape, and the irregularities of the free edge.
The thickened edges of the cusps are thinned out. The valve is tricuspidized by cutting the fused cusp at the raphae all the way to the aortic wall. The fused
portion of the cusps at the commissural level is opened to the wall as well. A piece of the treated autologous pericardium is tailored to fit the specific archi-
tecture of each cusp, but slightly oversized in depth (10%–15%) and length (up to 25%).
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mia of 32C is used. The aortic cannula is inserted at the distal aspect of
the ascending aorta close to the innominate artery. Myocardial preservation
is maintained with antegrade and retrograde cold, mostly continuous, blood
cardioplegia.
An oblique aortotomy incision is made, and each valve cusp is evaluated
as to the extent of tissue deficiency, the shape, and the irregularities of the
free edge. The thickened edges of the cusps are thinned out. The valve is
tricuspidized by cutting the fused cusp at the raphae all the way to the aortic
wall. The fused portion of the cusps at the commissural level is opened to the
wall. Any subcommissural fusion or scar tissue is released to provide max-
imal mobility of the cusps.
The ACEV technique consists of using a piece of the treated autologous
pericardium that is then tailored to fit the specific architecture of each cusp
(Figure 1), but slightly oversized in depth (10%–15%) and length (up to
25%). In particular, the width should provide enough additional depth to
the cusp so that the reconstructed cusp free edge is leveled with the sinotub-
ular bar at the commissures but deeper (more caudad) at the center. It is then
sutured to the cusp using continuous 5.0/6.0 polypropylene sutures from its
center toward the commissures. The sutures are placed in a radial fashion so
the distance between the suture-line on the pericardium is slightly wider
than that on the cusp to allow for a generous mural edge.
After completion of the pericardial extension of the 3 cusps, the depth of
each sinus is assessed. As a general rule, the center of the free edge of the
constructed cusp should reach the level of the sinotubular bar when pulled
superiorly. Any excess pericardial tissue is cut at this stage, leaving the com-
missural ends slightly more superior than the center, thus giving the cusp
edge the normal semilunar appearance (Figure 2).
The commissural ends of the constructed cusps are suspended at the level
of sinotubular bar using transmural pledgeted 4.0 or 5.0 polypropylene
sutures. The suspension is tailored to provide optimal cusp edge coaptation
but to avoid crowding of the subcommissural triangle.
In patients with severe dilatation of the ventriculoaortic junction, a reduc-
tion annuloplasty at the subcommissural area between right and left cusps is
performed to enhance coaptation. When the cusp is prolapsed, no attempt is
made to excise any portions, but rather to support the prolapsed segment
with a strip of autologous pericardium sutured to the edge of the cusp and
consequently suspended to the aortic wall as described.The Journal of Thoracic and CaIntraoperative transesophageal, and recently 3-dimensional, echocardi-
ography is typically used to define the anatomy of the valve and to assess
the repair (Figure 3).Statistical Analysis
Data are expressed as mean  standard deviation for continuous vari-
ables and as median and range for categoric variables. For comparison of
continuous and categoric variables between groups, independent-samples
t test and chi-square analyses, respectively, were used. Fisher’s exact test
was used to detect significant differences between groups. Unpaired 2-tailed
t test was performed for comparison of continuous variables between
groups. For comparison of preoperative and postoperative data within
patients, paired t test analysis was used.
The probability of freedom from events was estimated according to the
Kaplan–Meier method. The freedom-from-events estimates were com-
pared with the log-rank test. Univariate analysis was carried out using
a P value of less than .05 to determine predictors of early and late freedom
from valve reoperation or replacement. The Cox proportional hazards
regression model was used to identify variables. Significant factors were
entered into a multivariate logistic regression model to assess their inde-
pendent impact. Because of a high degree of covariance of variables, the
analysis was performed repeatedly, removing factors stepwise, to identify
the most important variables. The Statistical Package for the Social
Sciences 15.0.1 for Windows (SPSS Inc, Chicago, Ill) was used for
statistical analysis.
RESULTS
Twenty-six patients underwent at least 1 intervention
before ACEV at The Heart Institute for Children. Twenty-
four balloon valvuloplasties were performed in 20 patients.
Six patients underwent surgical valvotomy. Another 43
patients (19 with BAVs and 24 with congenital AS) had
valvuloplasty or valvotomy (other than ACEV) in outside
facilities. No patients required additional valvuloplasty/val-
votomy after ACEV.rdiovascular Surgery c Volume 139, Number 4 935
FIGURE 2. ACEV with tricuspidization. The width of each pericardial extension should provide enough additional depth to the cusp so that the recon-
structed cusp free edge is level with the sinotubular bar at the commissures but deeper (more caudad) at the center. It is then sutured to the cusp using con-
tinuous 5.0/6.0 polypropylene sutures from its center toward the commissures. The sutures are placed in a radial fashion so that the distance between the suture
line on the pericardium is slightly wider than that on the cusp to allow for a generous mural edge. After completion of the pericardial extension of the 3 cusps,
the depth of each sinus is assessed. As a general rule, the center of the free edge of the constructed cusp should reach the level of the sinotubular bar when
pulled superiorly, giving the cusp edge the normal semilunar appearance. The commissural ends of the constructed cusps are suspended at the level of sino-
tubular bar using transmural pledgeted 4.0 or 5.0 polypropylene sutures. The suspension is tailored to provide optimal cusps edges coaptation yet avoid crowd-
ing of the subcommissural triangle.
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moderate in 9 patients (6.5%). Of those with severe AI, 19
patients had a tricommissural valve with deficiency of 1 or
more leaflets (usually right or noncoronary leaflets), 1 patient
had a unicommissural valve and central deficiency, and the
remaining patients had a bicommissural valve with a central
deficiency. In all but 4 of these patients, AI was related to theFIGURE 3. ACEV. Perioperative transesophageal echocardiographic assessme
vuloplasty.
936 The Journal of Thoracic and Cardiovascular Surgarea of the right or noncoronary cusp. The cause was acquired
in 4 patients (2 with endocarditis, 2 with rheumatic carditis).
Among patients with only moderate AI, 2 had post-arte-
rial switch operation AI, 6 had traumatic AI after primary
valvuloplasty, and 1 had aortic root abscess.
Moderate AS was present in 39 patients (28%): after
previous treatment of AS in 26, 12 with BAVs (1 afternt. LVOT, Left ventricular outflow tract; ACEV, aortic cusp extension val-
ery c April 2010
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Dprimary valvuloplasty for BAVs), and after ventricular
septal defect repair in 1.
A combination of moderate-to-severe AS and moderate
AI was present in 42 patients (30.2%): 39 with congenital
AS/AI, after primary valvuloplasty treatment for BAVs in
2, and after primary valvuloplasty for congenital AS in 1.
There were no early, intermediate, or late deaths. After the
Ross operation (previously treated congenital AS with bal-
loon valvuloplasty and ACEV), a patient had intraoperative
cardiac arrest and as a result had a devastating irreversible
neurologic injury.
Crossclamp and CPB times were 69.6  18.6 and 95.1 
27.6 minutes, respectively. More than mild AS, AI, or
combined AS/AI, as documented by echocardiogram, were
considered nonacceptable intraoperative outcomes and justi-
fied reintervention. On this basis, reinstitution of CPB was
required after 8 (5.8%) ACEVs for residual moderate or
greater AS, AI, or combined-AS/AI. Re-repair was success-
fully performed in 6 patients (with only trace/mild AI). Two
patients underwent AVR.
ACEV was performed in all 139 patients. Tricuspidiza-
tion was performed in all patients with BAV. Additional pro-
cedures were performed in 8 patients. Ten patients hadTABLE 2. Aortic cusp extension valvuloplasty and results
Aortic cusp extension v
Outcomes I
Hospital mortality 0
Cumulative mortality 0
Hospital length of stay (d) 5.1  1.3
CPB time (min) 95.1  27.6
Crossclamp time (min) 69.6  18.6
Pacemaker system implantation 1 (0.7%)
Subacute bacterial endocarditis 1 (0.7%)
Second ACEV 16 (11.5%
Ross procedure 32 (23%)
Prosthetic AVR 16 (11.5%
Outcomes II
Postoperative ACEV AI or AS: none/trivial 54 (39%)
Postoperative ACEV AI or AS: mild 84 (60.3%
Postoperative ACEV AI or AS: moderate 1 (0.7%)
Postoperative ACEV AI or AS: severe 0
Outcomes III (at latest follow-up) Post-ACEV pre-AVR
Severe AI 23
Moderate AI 18
Mild/trivial AI 12
Severe AS 11
Moderate AS 27
Mild AS 14
LVEDD z-value 4.2  3.11
Aortic annulus z-value 2.3  1.25
Aortic sinus diameter z-value 4.4  1.21
Sinotubular junction diameter z-value 1.8  1.28
LV wall thickness z-value 2.9  1.32
AI, Aortic insufficiency; AS, aortic stenosis; ACEV, aortic cusp extension valvuloplasty; CP
end-diastolic diameter; NS, not significant; LV, left ventricular.
The Journal of Thoracic and Caundergone previous aortic coarctation repair (2 with associ-
ated ventricular septal defect repair and 2 with subaortic re-
section), 3 patients underwent an arterial switch operation,
and 1 patient underwent repair of an interrupted aortic arch
with ventricular septal defect.
Post-ACEV AI or AS was improved in 137 patients. AI or
AS was trivial or none in 54 patients (39%), mild in 84 pa-
tients (60.3%), and moderate in 1 patient (0.7%) (Table 2).
At most recent follow-up, in patients who underwent
AVR (vs those who did not undergo AVR), the degree of
AI was severe in 23 patients (vs none, P<.001) and moder-
ate in 18 patients (vs 3, P< .001). The degree of AS for the
same group of patients (vs those who had no AVR) was
severe in 11 patients (vs none, P< .001) and moderate in
27 patients (vs 2, P< .001). Z-values of LVEDD, aortic
annulus, aortic sinus diameter, sinotubular junction diame-
ter, and LV wall thickness between the 2 groups are shown
in Table 2.
During a median follow-up of 14.4 years (0.1–21.4 years),
64 patients underwent aortic valve reinterventions. A second
ACEV for recurrent AI or combined AS/AI was performed
in 16 patients at a median of 40.6 months (11–116). AVR
(Ross procedure or mechanical valve prosthesis) wasalvuloplasty
)
)
)
(n ¼ 48) Post-ACEV no AVR (n ¼ 91) P value
0 <.001
3 <.001
88 <.001
0 <.001
2 <.001
32 NS
1.8  1.32 <.001
1.1  0.95 <.001
2.3  1.91 <.001
1.3  1.03 NS
1.7  1.16 <.001
B, cardiopulmonary bypass; AVR, aortic valve replacement; LVEDD, left ventricular
rdiovascular Surgery c Volume 139, Number 4 937
FIGURE 4. Kaplan–Meier estimate of freedom from AVR after ACEV.
ACEV,Aortic cusp extension valvuloplasty; AVR, aortic valve replacement.
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after ACEV, at a mean age of 14.1 5.8 years. In 32 of 139
ACEVs (23%), the Ross operation was performed. The
Konno operation was added in 2 patients (6.2%) undergoing
the Ross operation. Other AVRs were performed after 16
ACEVs (11.5%) (Table 2).
Freedom from any reintervention at 18 years was 50.3%
 5.3%. Freedom from a second ACEV at 1, 5, 10, and 18
years was 99.1% 0.9%, 88.0% 3.3%, 82.1% 4.2%,
and 82.1% 4.2%, respectively. Freedom from any type of
AVR at 1, 5, 10, and 18 years was 97.6% 1.4%, 79.7%
4.3%, 71.8%  5.1%, and 60.0%  7.2%, respectively
(Figure 4).
By univariate analysis, gender, prior primary valvulo-
plasty, and weight at first ACEV were not significant factors
(P ¼ not significant) for AVR. The risk for AVR increased
with longer CPB (P .001) and crossclamp (P .042) times dur-
ing initial ACEV. BAV was associated with an increased
risk for AVR than combined congenital AS/AI (P< .001)
and congenital AS (P .005), as was congenital AS compared
with combined congenital AS/AI (P .008). None or trace
residual AS or AI was superior to mild or moderate residual
AS or AI after ACEV with regard to freedom from AVR
(P< .001). In multivariate analysis, shorter CPB (P .004)
and initial diagnosis of combined congenital AS/AI (P<
.001) after the first ACEV increased freedom from AVR.
In addition, mild or moderate residual AS or AI after the first
ACEV was associated with an increased risk for AVR (P<
.001) (Table 3).
A third-degree block developed in 1 patient after ACEV,
who required a pacemaker at day 12 postoperatively. One
patient had subacute bacterial endocarditis 4.4 months after
ACEV (Table 2).
DISCUSSION
Better understanding of the natural history and morphol-
ogy of congenitally or acquired abnormal aortic valve,
advances in surgical techniques and intraoperative myocar-938 The Journal of Thoracic and Cardiovascular Surgdial protection, and comprehensive postoperative manage-
ment have contributed to a remarkable improvement in
early and late mortality. Applicability, durability, and
long-term outcomes of different types of aortic valve repair
have not been thoroughly analyzed.
This series was intended to focus on patients with
complex anatomy in whom ACEV with tricuspidization
(when needed) was exclusively used. Simple lesions, such
as isolated AS, less than moderate AI, or simple iatro-
genic-associated AI, for which the usual techniques of repair
have proved durable, were excluded.11-15 Balloon or surgi-
cal aortic valvuloplasty may be an effective and safe initial
treatment for patients with AS.16,17 Contrary to other
reports,18 no patients had any form of surgical or balloon
valvuloplasty after ACEV.
In our experience, ACEV was effective at acutely reduc-
ing AI or AS and improving LV wall mass thickness and
dimensions in children and adolescents with AI or AS
from a variety of causes. Other investigators have reported
similarly promising early outcomes after ACEV in children
and adolescents with congenital heart disease, although most
series are relatively small or include simple and complex
repairs.7-14,18,19 Nevertheless, the literature suggests that
ACEV is effective in the short term and, as well shown in
this study, allows expeditious LV remodeling even in pa-
tients with significant LV dilation or wall mass thickness
with satisfying long-term durability and freedom fromAVR.
Despite the limited data regarding advanced valvuloplasty
techniques in children with complex aortic valve disease, the
literature concerning the use of pericardial leaflet extension
in both children and adults with rheumatic AI and in adults
with AI and a structurally normal aortic valve demonstrates
that repairs incorporating pericardial augmentation of cusps
can be fairly durable.13-15,18,19 There are several important
features related to ACEV with tricuspidization. It provides
a comprehensive repair and restores all the important ana-
tomic features of the aortic valve. By fashioning the pericar-
dial patch to fit the deficient parts of each cusp, normal depth
of the sinuses is reestablished and adequate cusp coaptation
is secured. Cusp resuspension at the level of sinotubular bar
without central valve crowding and wide subcommissural
triangle are essential elements of ACEV. Furthermore, tri-
cuspidization restores central flow characteristics and,
thus, decreases turbulence and subsequent trauma to the re-
paired cusps. The ultimate outcomes are often contingent on
the performance of the patch used. We have no experience
with patch substitutes other than autologous pericardium at
the present time. Autologous pericardium is fairly pliable
and easily accessible, and can be fashioned to any shape
needed. Concentration of glutaraldehyde solution and dura-
tion of preinsertion pericardial treatment have varied
throughout the study period. In our early series, the pericar-
dial extensions were often heavily calcified and contracted,
presumably contributing to progressive post-ACEV aorticery c April 2010
TABLE 3. Incremental risk factors associated with reoperation for aortic valve replacement after aortic cusp extension valvuloplasty: Univariate
and multivariate Cox regression analyses
Univariate Cox model Multivariate Cox model
Variable HR 95% CI P HR 95% CI P
Gender 1.29 (0.69–2.42) .43
Younger age at ACEV (<9.3 y) 0.98 (0.94–1.02) .36 0.92 (0.87–0.98) .004
Prior plasty 1.54 (0.80–2.99) .21
Weight at ACEV 1.00 (0.98–1.01) .71
ACEV CPB time (min) 1.02 (1.01–1.03) .001 1.02 (1.01–1.03) <.001
ACEV crossclamp
time (min)
1.01 (1.00–1.02) .042 —*
BAV 2.88 (1.62–5.13) <.001 0.08 (0.02–0.34) <.001
Combined congenital AS/AI 0.63 (0.33–1.22) .16
Congenital AS 0.09 (0.02–0.38) <.001 0.42 (0.20–0.85) .013
Aortic coarctation 2.54 (1.07–6.02) .058
ACEV residual AS or AI 7.00 (2.76–17.73) <.001 6.02 (2.29–15.81) <.001
HR, Hazard ratio; CI, confidence interval; ACEV, aortic cusp extension valvuloplasty; CPB, cardiopulmonary bypass; BAV, bicuspid aortic valve; AS, aortic stenosis; AI, aortic
insufficiency. *Not included in multivariate model.
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0.625% glutaraldehyde solution for shorter duration (3 min-
utes), compared with our early experience,20 and kept moist
with normal saline. This might promote increased pericar-
dial pliability and decrease the incidence of restenosis; how-
ever, the effect of this modification has yet to be determined.
The optimal timing and method of intervention remain
a challenging task. Guidelines for aortic valve surgery in
this patient population traditionally have been developed
on the basis of those for adults. Results with ACEV encour-
age earlier and more aggressive management in pediatric
patients because the LV has to preserve function for a longer
life span. On the basis of our experience and those of
others,7,10,13,14,17-19,21 we advocate ACEV in all patients
with moderate or severe AI, moderate AS, or a combination
of moderate-to-severe AS and moderate AI as long as they
have a normally sized aortic annulus (z-value, 1.5 or
greater) without LV hypoplasia or mitral valve hypoplastic
annulus (z-value,2.0 or smaller). Timing is rather critical.
Several echocardiographic/Doppler-derived indices, such
as pressure gradient, LV hypertrophy progression, LVEDD
z-value, and ratio of regurgitant jet/annulus diameter (as pre-
viously described), may guide optimal timing and strategy.
Mid- and long-term survival varies in the litera-
ture.6-15,18,19 There were no early, intermediate, or late
deaths in our series.
Although freedoms from any aortic valve reintervention
or AVR vary between different series, published studies
have demonstrated progressively decreasing freedom from
aortic valve reintervention after various surgical valvulo-
plasty techniques.10-14,18,19,21 Ours is among the longest in
the literature.
One of the potential adverse outcomes of ACEV for AI in
patients with congenitally abnormal valves is postoperative
AS. This is a particular concern in patients in whom AIThe Journal of Thoracic and Cadeveloped after balloon or surgical valvuloplasty for
AS.16,17 In our experience, new or worsening AS after
ACEV was rare. However, AS did develop over time. The
cause of this progressive AS is not clear, but pericardial
calcification or contraction might contribute. In those who
underwent AVR, the degree of AS at the most recent
follow-up after ACEV was severe in 7.9% and moderate
in 19.4%. On the basis of this observation, we have recently
favored the Ross procedure over ACEV in patients with
moderate/severe AS and aortic annulus with z-value 
1.5 because of the concern for early failure and recurrence
of AS over time.
In contrast with the findings of others,22 the z-values of
LVEDD, aortic annulus, aortic sinus diameter, sinotubular
junction diameter, and LV wall thickness, which improved
after ACEV, remained relatively stable at follow-up in
patients whomet no AVR criteria at the latest follow-up after
ACEV.
On the basis of multivariate regression analysis, shorter
CPB and initial diagnosis of combined congenital AS/AI
at the first ACEV increase freedom from AVR. In addition,
mild or moderate residual AS or AI after the first ACEV is
associated with an elevated risk for AVR. LV dimensions
typically normalize or improve substantially after ACEV
even when severe dilation is present. ACEV allows substan-
tial delay of AVR for most patients, which may facilitate
eventual AVR with a larger prosthesis or Ross procedure.
As a result, with improved patient selection and surgical
techniques, the durability of ACEV should continue to
improve.
There are advocates of the Ross procedure as first-line
management in children and adolescents with congenitally
abnormal aortic valve disease and a normally sized aortic an-
nulus.3-5,23-25 Our experience with ACEV in this complex
population with aortic valve disease suggests that unlessrdiovascular Surgery c Volume 139, Number 4 939
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Dcertain criteria are fulfilled (as outlined above), and despite
certain drawbacks, the Ross procedure or prosthetic AVR
remains an alternative to ACEV in our practice. The Ross
procedure involves replacement of the entire aortic root,
with reimplantation of the coronary arteries, as well as place-
ment of a valved conduit between the right ventricle and the
pulmonary arteries. Apart from the need for conduit replace-
ment, there is increasing evidence of significant progressive
neoaortic root dilation and autograft failure. As an alterna-
tive to the Ross procedure, prosthetic AVR involves a risk
of early and late mortality in younger children receiving
smaller mechanical valves. It is associated with increased
frequency of complications, including morbidity related to
long-term anticoagulation if mechanical prosthesis is used,
deterioration of ventricular function caused by the develop-
ment of patient–prosthesis mismatch as the child outgrows
the initial valve, and the need for subsequent prosthetic valve
replacement.5,23-25
Study Limitations
The limitations of our study involve all the aspects of
a clinical retrospective, nonrandomized comparison analy-
sis. This study is limited by the heterogeneous patient pop-
ulation and by the fact that referral for surgery was
subjective in most cases. Furthermore, this experience
encompasses a period when the techniques of ACEV were
under development. Regular serial echocardiographic
assessment of pre-ACEV geometry and function was not
available, which limits our insight into the evolution of
changes in aortic valve function and LV size and function
with time. A study is in progress to evaluate the 3-dimen-
sional echocardiographic parameters of an abnormal aortic
valve that may help to guide selective intraoperative man-
agement. Finally, despite the relative benefits and drawbacks
of ACEV in comparison with therapeutic alternatives, this
study cannot be considered for direct comparison between
ACEV and AVR.
CONCLUSIONS
ACEV is a safe, effective, and reproducible surgical
option with excellent survival and good long-term outcomes
in children and adolescents with congenital or acquired aor-
tic valve disease. We favor the Ross or Ross–Konno opera-
tion over ACEV in patients with moderate/severe AS and
aortic annulus with z-value 1.5 because of the concern
for early failure and recurrence of AS over time. Patients
with a normally sized aortic annulus who have moderate
or severe AI, moderate AS, or a combination of moderate-
to-severe AS and moderate AI should be considered for
ACEV with tricuspidization (when needed). Pressure gradi-
ent, LV hypertrophy progression, LVEDD z-value, and ratio
of regurgitant jet/annulus diameter may guide optimal tim-
ing and strategy. ACEV provides acceptable durability and
satisfactory freedom from AVR.940 The Journal of Thoracic and Cardiovascular SurgReferences
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DDiscussion
Dr Ross M. Ungerleider, MD (Cleveland, Ohio). The topic is
timely. It is controversial and important as we try to find ways to
extend the time before valve replacement in our young population.
I want to ask you some questions that can help us understand
when to use your techniques in lieu of more conventional treat-
ments. I have spent a lot of time trying to understand the numbers
in your article and the numbers you presented today. Your study, as
you mentioned, is retrospective. It lacks comparison with a control
group treated by more conventional means, and as youmentioned it
also is subject to selection bias. You mentioned that you only
selected the patients with more complex problems. The patients
with more typical problems were treated by more usual techniques.
So for which patient is ACEVwith or without tricuspidization more
desirable than simple balloon valvotomy? You had 50 patients with
BAV and 40 patients with congenital AS, most aged more than 2
years. These patients would likely be treated in most centers by bal-
loon valvotomy, but only 20% of your patients in these groups have
balloon valvotomy before ACEV. Can you give us insight into why
you selected your patients for ACEV versus valvotomy and do you
have any outcome data comparing themwith the patient groups that
you apparently selected for simple valvotomy? I am having trouble
understanding why an ACEV was necessary for these patients with
predominant AS.
The literature would tend to support that freedom from AVR is
excellent after balloon valvotomy for older patients similar to the
ones in your series. For the patients who had AI, you had 41
patients with AS/AI and 8 patients with what you called other valve
pathology, yet you state that 49 patients received ACEV for severe
AI and an additional 9 patients received ACEV for moderate AI.
Does that number include a crossover from the bicuspid or congen-
ital AS group? As I looked at your numbers, it appeared that 44% of
patients in your series had ACEV for AI, leaving 56% having
ACEV for predominantly AS. This is potentially useful data for
you to have because you can create some comparison groups. Do
you have data to show if there is a difference in the freedom
from AVR in one group versus another? In particular, it might be
useful if you could compare for us the results of ACEV for AI
versus ACEV for AS and then ACEV plus tricuspidization for
AS, which is a uniquely different treatment group.
I am particularly concerned that you have not really explained to
us the benefits of tricuspidization compared with simple valvotomy
for BAV, and it would be helpful if you could determine whether
the ACEV group fared better than the balloon valvotomy groupThe Journal of Thoracic and Cafor AS in terms of putting off the time until AVR in these simi-
lar-aged patients. I am puzzled about the role for ACEV. Without
randomization and comparison with controls (simple valvotomy),
it is difficult to understand whether there is any useful role for
ACEV as you have described it.
You mentioned that you changed to a less intense fixation of
pericardium to improve the results of your ACEV, yet you don’t
give us any indication of what the problems were with the more
intensely treated pericardium. I wonder if you have any experience
with polytetrafluoroethylene (Gore-Tex; WL Gore & Associates,
Newark, DE) membrane for aortic cusp valve extension. I have
had good results so far with that.
Finally, going forward with your experience, as you help us
understand when to select patients for ACEV, what would you rec-
ommend for a 6-year-old with BAV, a normal annulus, a mean gra-
dient of 60 mm Hg, no AI, and an increase in LV wall mass?
Dr Polimenakos. Starting with your first comment and ques-
tion, I would say that most of these patients who present actually
require complex repair. We excluded patients who had simple val-
votomies or valvuloplasties that did not require extensive recon-
struction in the form of ACEV. That includes a group of patients
who had original valvotomy or valvuloplasty, and they did not
reach that level of AI to justify ACEV. As I mentioned to you be-
fore, I think if we have a gradually increased LVED after balloon
valvuloplasty, in that subset of patients you mentioned, and in
addition to that there is a regurgitant jet to aortic annulus diameter
greater than 35% to 40%, we recommend ACEV for these patients.
I totally agree with you that the specific subset of patients with
congenital AS is a group with early failure and recurrent AS.
That is why according to the original experience, over the last
few years we have been very selective offering ACEV to this sub-
category of patients. We encourage these patients to have some
form of valve replacement (probably in the form of Ross), particu-
larly the smaller patients.
In terms of your second question, there are some crossovers as
you mentioned. That is because a lot of the patients with BAV
had either predominantly AI when they presented to us, as a referral
center, or combined AI/AS. Some of them had even balloon valvu-
loplasty before that. That is why, as I mentioned, it is not a simple
repair that we just reinforce the commissure or repair a torn cusp.
Most of these patients have moderate to severe AI or a combination
AI and AS. Again, patients with congenitally related AS were one
of the subgroups originally attempted to be repaired, but currently
we do not recommend this technique, especially if the aortic valve
annulus has a z-value of1.5 or less.
In terms of your final question, this is actually an ongoing study.
We are going to look into the different surgical eras because, as I
mentioned to you before, we moved from glutaraldehyde-treated
autologous pericardium with 10 minutes of glutaraldehyde treat-
ment gradually down to, currently, 3 minutes.
Dr Ungerleider. But you switched because you were seeing
more progressive AI?
Dr Polimenakos. We were seeing more neocusp calcification
and fibrosis with predominantly AI. Some of these patients pre-
sented with combined recurrent AI and AS as well.rdiovascular Surgery c Volume 139, Number 4 941
